FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors
RegulatoryapprovedRetevmoPositive
AI Analysis
Summary
The FDA granted traditional approval to Eli Lilly's selpercatinib (Retevmo) on July 14, 2026, for locally advanced or metastatic RET fusion-positive solid tumors in adult and pediatric patients age two and older.
Outcome Details
FDA granted traditional approval for adult and pediatric patients two years of age and older
Importance:8/10
Sentiment:
0.90
FDA approvaloncologyRET fusion-positivesolid tumorspediatric indication
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 14, 2026 10:07 PM